GTX Stock Price, News & Analysis (NASDAQ:GTXI)

$12.80 0.28 (2.24 %)
(As of 12/11/2017 04:00 PM ET)
Previous Close$12.52
Today's Range$12.26 - $13.00
52-Week Range$2.73 - $13.35
Volume34,486 shs
Average Volume79,042 shs
Market Capitalization$269.69 million
P/E RatioN/A
Dividend YieldN/A
Beta1.76

About GTX (NASDAQ:GTXI)

GTX logoGTx, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs). Its lead product candidate, enobosarm (GTx-024), had been evaluated in over 24 completed or ongoing clinical trials, including in approximately six Phase II and two Phase III clinical trials. The Company is also engaged in the development of GTx-758 (Capesaris), an oral nonsteroidal selective estrogen receptor alpha agonist, for secondary hormonal therapy in men with metastatic and high-risk non-metastatic castration resistant prostate cancer (CRPC). Its product candidate, Enobosarm, for the treatment of women with advanced androgen receptor (AR) positive triple-negative breast cancer (TNBC), is in Phase II clinical development-stage.

Receive GTXI News and Ratings via Email

Sign-up to receive the latest news and ratings for GTXI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:GTXI
CUSIP40052B10
Phone901-523-9700

Debt

Debt-to-Equity RatioN/A
Current Ratio6.01%
Quick Ratio6.01%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.25 per share
Price / Book10.24

Profitability

Trailing EPS($1.76)
Net Income$-17,720,000.00
Net MarginsN/A
Return on Equity-123.92%
Return on Assets-98.13%

Miscellaneous

Employees26
Outstanding Shares21,540,000

GTX (NASDAQ:GTXI) Frequently Asked Questions

What is GTX's stock symbol?

GTX trades on the NASDAQ under the ticker symbol "GTXI."

How were GTX's earnings last quarter?

GTx, Inc. (NASDAQ:GTXI) announced its quarterly earnings data on Tuesday, November, 14th. The biopharmaceutical company reported ($0.53) EPS for the quarter, missing the Zacks' consensus estimate of ($0.28) by $0.25. View GTX's Earnings History.

Where is GTX's stock going? Where will GTX's stock price be in 2017?

2 Wall Street analysts have issued 12 month price targets for GTX's stock. Their forecasts range from $17.00 to $17.00. On average, they anticipate GTX's stock price to reach $17.00 in the next twelve months. View Analyst Ratings for GTX.

Who are some of GTX's key competitors?

Who are GTX's key executives?

GTX's management team includes the folowing people:

  • Robert James Wills Ph.D., Executive Chairman of the Board
  • Marc S. Hanover, Chief Executive Officer, Director
  • Jason T. Shackelford, Senior Director, Accounting and Corporate Controller, and Principal Financial and Accounting Officer
  • Henry P. Doggrell Sr., Vice President, Chief Legal Officer, Secretary
  • Diane C Young M.D., Vice President, Chief Medical Officer
  • , Bio & Compensation - 
  • Joseph R. Hyde III, Lead Director
  • Garry Neil M.D., Director
  • , Bio & Compensation - 
  • Michael G. Carter M.D., Independent Director
  • J. Kenneth Glass, Independent Director
  • Kenneth S. Robinson M.D., Independent Director

Who owns GTX stock?

GTX's stock is owned by many different of institutional and retail investors. Top institutional shareholders include HYDE JOSEPH R III (38.50%), PYRAMID PEAK FOUNDATION (29.52%), Abingworth LLP (2.11%) and Caxton Corp (0.39%). Company insiders that own GTX stock include J Kenneth Glass, Marc Steven Hanover, Peak Foundation Pyramid and Robert James Wills. View Institutional Ownership Trends for GTX.

Who bought GTX stock? Who is buying GTX stock?

GTX's stock was purchased by a variety of institutional investors in the last quarter, including Abingworth LLP and Caxton Corp. Company insiders that have bought GTX stock in the last two years include J Kenneth Glass, Marc Steven Hanover, Peak Foundation Pyramid and Robert James Wills. View Insider Buying and Selling for GTX.

How do I buy GTX stock?

Shares of GTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GTX's stock price today?

One share of GTX stock can currently be purchased for approximately $12.80.

How big of a company is GTX?

GTX has a market capitalization of $269.69 million. The biopharmaceutical company earns $-17,720,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis. GTX employs 26 workers across the globe.

How can I contact GTX?

GTX's mailing address is 175 TOYOTA PLAZA 7TH FLOOR, MEMPHIS TN, 38103. The biopharmaceutical company can be reached via phone at 901-523-9700 or via email at [email protected]


MarketBeat Community Rating for GTX (GTXI)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  100 (Vote Outperform)
Underperform Votes:  102 (Vote Underperform)
Total Votes:  202
MarketBeat's community ratings are surveys of what our community members think about GTX and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

GTX (NASDAQ:GTXI) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyHoldHold
Consensus Rating Score: 2.672.502.002.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $9.00$1.00$1.00$1.00
Price Target Upside: 19.06% downside86.68% downside28.21% upside28.21% upside

GTX (NASDAQ:GTXI) Consensus Price Target History

Price Target History for GTX (NASDAQ:GTXI)

GTX (NASDAQ:GTXI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/21/2017Robert W. BairdInitiated CoverageOutperform -> Outperform$17.00N/AView Rating Details
11/9/2017Stifel NicolausInitiated CoverageBuy -> BuyN/AView Rating Details
9/9/2016Jefferies GroupReiterated RatingHold$1.00N/AView Rating Details
(Data available from 12/11/2015 forward)

Earnings

GTX (NASDAQ:GTXI) Earnings History and Estimates Chart

Earnings by Quarter for GTX (NASDAQ:GTXI)

GTX (NASDAQ GTXI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2017Q3 2017($0.28)($0.53)ViewN/AView Earnings Details
8/14/2017Q2 2017($0.40)ViewN/AView Earnings Details
5/15/2017Q1 2017($0.39)ViewN/AView Earnings Details
3/15/2017Q4 2016($0.57)($0.44)ViewN/AView Earnings Details
11/3/2016Q3($0.05)($0.05)ViewN/AView Earnings Details
8/9/2016Q2($0.05)($0.04)ViewN/AView Earnings Details
5/10/2016Q1($0.04)$0.01ViewN/AView Earnings Details
3/3/2016Q415($0.10)($0.04)ViewListenView Earnings Details
10/29/2015Q315($0.06)($0.04)ViewListenView Earnings Details
8/6/2015Q215($0.04)($0.03)ViewListenView Earnings Details
5/8/2015Q1($0.04)($0.04)ViewListenView Earnings Details
3/4/2015Q314($0.07)($0.05)ViewListenView Earnings Details
11/10/2014Q214($0.10)($0.06)ViewListenView Earnings Details
8/5/2014Q2($0.11)($0.15)ViewN/AView Earnings Details
5/8/2014Q114($0.12)($0.14)ViewN/AView Earnings Details
3/4/2014Q413($0.13)($0.12)ViewListenView Earnings Details
11/12/2013Q313($0.21)($0.14)ViewListenView Earnings Details
7/19/2013Q2 2013($0.22)($0.20)ViewN/AView Earnings Details
5/3/2013Q1 2013($0.21)($0.20)ViewListenView Earnings Details
2/21/2013Q4 2012($0.21)($0.17)ViewListenView Earnings Details
11/8/2012Q312($0.17)$0.12$1.93 millionViewN/AView Earnings Details
8/8/2012($0.17)($0.17)ViewN/AView Earnings Details
5/8/2012($0.17)($0.18)ViewN/AView Earnings Details
2/21/2012($0.17)($0.17)ViewN/AView Earnings Details
11/4/2011($0.18)($0.15)ViewN/AView Earnings Details
8/9/2011($0.19)($0.21)ViewN/AView Earnings Details
5/9/2011($0.13)($0.05)ViewN/AView Earnings Details
2/24/2011($0.16)($0.16)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

GTX (NASDAQ:GTXI) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.61 EPS
Next Year EPS Consensus Estimate: $-1.68 EPS

Dividends

Dividend History for GTX (NASDAQ:GTXI)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

GTX (NASDAQ GTXI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 41.20%
Institutional Ownership Percentage: 11.57%
Insider Trades by Quarter for GTX (NASDAQ:GTXI)
Insider Trades by Quarter for GTX (NASDAQ:GTXI)

GTX (NASDAQ GTXI) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/14/2016Peak Foundation PyramidMajor ShareholderBuy7,716,049$0.81$6,249,999.69View SEC Filing  
6/16/2016Robert James WillsChairmanBuy100,000$0.65$65,000.00View SEC Filing  
3/1/2016J Kenneth GlassDirectorBuy44,000$0.60$26,400.00View SEC Filing  
1/26/2016Marc Steven HanoverCEOBuy4,000$0.65$2,600.00View SEC Filing  
1/25/2016Marc Steven HanoverCEOBuy12,813$0.63$8,072.19View SEC Filing  
1/19/2016Marc Steven HanoverCEOBuy25,000$0.50$12,500.00View SEC Filing  
1/14/2016Marc Steven HanoverCEOBuy25,000$0.49$12,250.00View SEC Filing  
12/24/2015J Kenneth GlassDirectorBuy100$0.79$79.00View SEC Filing  
12/22/2015J Kenneth GlassDirectorBuy1,907$0.78$1,487.46View SEC Filing  
12/21/2015J Kenneth GlassDirectorBuy39,900$0.78$31,122.00View SEC Filing  
5/19/2015J Kenneth GlassDirectorBuy24,500$1.25$30,625.00View SEC Filing  
5/14/2015Robert James WillsChairmanBuy46,140$0.96$44,294.40View SEC Filing  
5/8/2015Henry Patton DoggrellVPBuy25,477$0.80$20,381.60View SEC Filing  
5/8/2015Robert James WillsChairmanBuy50,000$0.80$40,000.00View SEC Filing  
4/22/2015J Kenneth GlassDirectorBuy10,000$0.72$7,200.00View SEC Filing  
4/21/2015J Kenneth GlassDirectorBuy11,608$0.71$8,241.68View SEC Filing  
4/15/2015J Kenneth GlassDirectorBuy3,300$0.72$2,376.00View SEC Filing  
4/10/2015J Kenneth GlassDirectorBuy16,400$0.67$10,988.00View SEC Filing  
9/23/2014Marc Steven HanoverCEOBuy5,000$0.75$3,750.00View SEC Filing  
9/17/2014Marc Steven HanoverCEOBuy10,000$0.74$7,400.00View SEC Filing  
8/21/2014Marc Steven HanoverCEOBuy20,000$1.00$20,000.00View SEC Filing  
8/19/2014Marc Steven HanoverCEOBuy10,000$1.01$10,100.00View SEC Filing  
8/8/2014Henry Patton DoggrellVPBuy10,000$0.97$9,700.00View SEC Filing  
8/8/2014Marc Steven HanoverCEOBuy30,000$0.93$27,900.00View SEC Filing  
8/7/2014Jason T ShackelfordInsiderBuy10,000$0.92$9,200.00View SEC Filing  
8/7/2014Marc Steven HanoverCEOBuy30,000$0.92$27,600.00View SEC Filing  
6/6/2014James T DaltonVPSell72,883$1.30$94,747.90View SEC Filing  
3/21/2014Jack Schulermajor shareholderSell1,192,251$1.84$2,193,741.84View SEC Filing  
8/22/2013Jack Schulermajor shareholderBuy93,777$1.36$127,536.72View SEC Filing  
8/21/2013Jack Schulermajor shareholderBuy309,591$1.42$439,619.22View SEC Filing  
7/9/2013Mark Edward MostellerCFOSell17,000$6.99$118,830.00View SEC Filing  
1/17/2013James T DaltonVPSell20,000$5.20$104,000.00View SEC Filing  
12/14/2012Timothy R G SearDirectorBuy50,000$4.33$216,500.00View SEC Filing  
8/27/2012J Kenneth GlassDirectorBuy10,000$3.76$37,600.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

GTX (NASDAQ GTXI) News Headlines

Source:
DateHeadline
GTx, Inc. (GTXI) Expected to Announce Earnings of -$0.39 Per ShareGTx, Inc. (GTXI) Expected to Announce Earnings of -$0.39 Per Share
www.americanbankingnews.com - November 26 at 7:08 AM
Pre-Open Movers 11/21: (CLSN) (PANW) (SNSS) Higher; (CYTK) (QD) (SIG) Lower (more...)Pre-Open Movers 11/21: (CLSN) (PANW) (SNSS) Higher; (CYTK) (QD) (SIG) Lower (more...)
www.streetinsider.com - November 21 at 7:17 PM
GTx, Inc. (GTXI) Coverage Initiated by Analysts at Robert W. BairdGTx, Inc. (GTXI) Coverage Initiated by Analysts at Robert W. Baird
www.americanbankingnews.com - November 21 at 7:06 AM
GTx reports 3Q lossGTx reports 3Q loss
finance.yahoo.com - November 16 at 3:25 PM
GTx, Inc. (GTXI) Releases  Earnings Results, Misses Expectations By $0.25 EPSGTx, Inc. (GTXI) Releases Earnings Results, Misses Expectations By $0.25 EPS
www.americanbankingnews.com - November 15 at 12:54 PM
GTx Provides Corporate Update and Reports Third Quarter 2017 Financial ResultsGTx Provides Corporate Update and Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 14 at 7:51 PM
 Analysts Set $16.00 Target Price for GTx, Inc. (GTXI) Analysts Set $16.00 Target Price for GTx, Inc. (GTXI)
www.americanbankingnews.com - November 11 at 9:24 PM
Analyzing GTx (GTXI) & Brainstorm Cell Therapeutics (BCLI)Analyzing GTx (GTXI) & Brainstorm Cell Therapeutics (BCLI)
www.americanbankingnews.com - November 8 at 7:28 PM
GTx, Inc. to Participate in the Stifel 2017 Healthcare ConferenceGTx, Inc. to Participate in the Stifel 2017 Healthcare Conference
finance.yahoo.com - November 8 at 8:37 AM
BRIEF-GTX Inc files for offering of up to 8.8 million shares of common stockBRIEF-GTX Inc files for offering of up to 8.8 million shares of common stock
www.reuters.com - October 20 at 11:07 PM
Analyzing GTx (GTXI) & Blueprint Medicines Corporation (BPMC)Analyzing GTx (GTXI) & Blueprint Medicines Corporation (BPMC)
www.americanbankingnews.com - October 8 at 6:16 PM
BRIEF-Aisling capital IV LP reports 6.2 pct passive stake in GTX as of Sept 29BRIEF-Aisling capital IV LP reports 6.2 pct passive stake in GTX as of Sept 29
www.reuters.com - October 7 at 12:50 AM
GO Therapeutics appoints Dr. Robert J. Wills to Board of DirectorsGO Therapeutics appoints Dr. Robert J. Wills to Board of Directors
globenewswire.com - October 5 at 2:31 PM
GTx Announces Closing Of $48.5 Million Private PlacementGTx Announces Closing Of $48.5 Million Private Placement
www.thestreet.com - September 29 at 4:37 PM
BRIEF-GTx announces $48.5 million private placementBRIEF-GTx announces $48.5 million private placement
www.reuters.com - September 27 at 5:14 PM
Memphis drug developer announces $48.5 private placementMemphis drug developer announces $48.5 private placement
www.bizjournals.com - September 27 at 5:14 PM
GTx Announces Webcast of Corporate Presentation at the 2017 Cantor Fitzgerald Global Healthcare ConferenceGTx Announces Webcast of Corporate Presentation at the 2017 Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 26 at 11:23 AM
GTx to Host Key Opinion Leader Luncheon on the Topic of Stress Urinary Incontinence on September 28 th in New York CityGTx to Host Key Opinion Leader Luncheon on the Topic of Stress Urinary Incontinence on September 28 th in New York City
www.businesswire.com - September 23 at 6:50 PM
GTx to Host Key Opinion Leader Luncheon on the Topic of Stress Urinary Incontinence on September 28th in New York CityGTx to Host Key Opinion Leader Luncheon on the Topic of Stress Urinary Incontinence on September 28th in New York City
finance.yahoo.com - September 22 at 1:17 PM
GTx (GTXI) vs. Its Peers Financial ComparisonGTx (GTXI) vs. Its Peers Financial Comparison
www.americanbankingnews.com - September 19 at 12:48 AM
Comparing GTx (GTXI) and Its PeersComparing GTx (GTXI) and Its Peers
www.americanbankingnews.com - September 16 at 6:30 PM
GTx, Inc. (GTXI) Reports ositive Results from Enobosarm Phase 2 Proof-of-Concept Clinical Trial in Women with SUIGTx, Inc. (GTXI) Reports ositive Results from Enobosarm Phase 2 Proof-of-Concept Clinical Trial in Women with SUI
www.streetinsider.com - September 14 at 7:58 PM
GTxs (GTXI) Enobosarm Positive in Phase II, Shares DownGTx's (GTXI) Enobosarm Positive in Phase II, Shares Down
finance.yahoo.com - September 14 at 7:58 PM
GTx's (GTXI) Enobosarm Positive in Phase II, Shares DownGTx's (GTXI) Enobosarm Positive in Phase II, Shares Down
finance.yahoo.com - September 14 at 7:58 PM
GTx Announces Positive Results from Enobosarm Phase 2 Proof-of-Concept Clinical Trial in Women with Stress Urinary IncontinenceGTx Announces Positive Results from Enobosarm Phase 2 Proof-of-Concept Clinical Trial in Women with Stress Urinary Incontinence
finance.yahoo.com - September 14 at 4:00 AM
GTx, Inc. (GTXI) Releases  Earnings ResultsGTx, Inc. (GTXI) Releases Earnings Results
www.americanbankingnews.com - August 15 at 1:10 PM
GTx Provides Corporate Update and Reports Second Quarter 2017 Financial ResultsGTx Provides Corporate Update and Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 14 at 7:38 PM
GTx reports 2Q lossGTx reports 2Q loss
finance.yahoo.com - August 14 at 7:38 PM
Astellas Head of Medical Affairs Americas Shontelle Dodson Joins National Pharmaceutical Council Board of DirectorsAstellas Head of Medical Affairs Americas Shontelle Dodson Joins National Pharmaceutical Council Board of Directors
www.bizjournals.com - July 14 at 2:49 AM
GTx Discusses Key Goals with WSAGTx Discusses Key Goals with WSA
finance.yahoo.com - July 12 at 7:59 PM
GTxs (GTXI) Enobosarm Positive in Phase II Study; Shares UpGTx's (GTXI) Enobosarm Positive in Phase II Study; Shares Up
www.zacks.com - June 15 at 12:03 AM
Veru Healthcare: The Merger And What Lies AheadVeru Healthcare: The Merger And What Lies Ahead
seekingalpha.com - June 13 at 11:09 AM
GTx Hikes on Treatment Test ResultsGTx Hikes on Treatment Test Results
www.baystreet.ca - June 13 at 11:09 AM
GTx, Inc. (GTXI) Releases Preliminary Results from Ongoing Phase 2 Proof-of-Concept Clinical Trial in Women with SUIGTx, Inc. (GTXI) Releases Preliminary Results from Ongoing Phase 2 Proof-of-Concept Clinical Trial in Women with SUI
www.streetinsider.com - June 13 at 11:09 AM
GTx Inc. (GTXI) Jumped To A 4-Month High On Study ResultsGTx Inc. (GTXI) Jumped To A 4-Month High On Study Results
www.rttnews.com - June 13 at 11:09 AM
Mid-Day Market Update: Crude Oil Up 1%; GTx Shares Spike HigherMid-Day Market Update: Crude Oil Up 1%; GTx Shares Spike Higher
feeds.benzinga.com - June 12 at 12:43 PM
GTxs enobosarm shows treatment effect in mid-stage study in postmenopausal women with stress urinary incontinence; shares up 14% premarketGTx's enobosarm shows treatment effect in mid-stage study in postmenopausal women with stress urinary incontinence; shares up 14% premarket
seekingalpha.com - June 12 at 8:28 AM
Drugmakers and biotechs increasingly view Trump as a business riskDrugmakers and biotechs increasingly view Trump as a business risk
www.bizjournals.com - May 19 at 10:06 AM
Biotech firms increasingly view Trump as a business riskBiotech firms increasingly view Trump as a business risk
www.bizjournals.com - May 17 at 5:34 PM
BRIEF-GTX reports Q1 net loss per share of $0.39BRIEF-GTX reports Q1 net loss per share of $0.39
www.reuters.com - May 16 at 11:27 AM
GTx Announces Acceptance of an Abstract on Preliminary Results from Phase 2 Clinical Trial in Women with Stress Urinary Incontinence at the International Continence Society ...GTx Announces Acceptance of an Abstract on Preliminary Results from Phase 2 Clinical Trial in Women with Stress Urinary Incontinence at the International Continence Society ...
www.businesswire.com - May 12 at 6:14 PM
GTx, Inc. (GTXI) Reports Preclinical Study Results of SARMs in DMD Models Published in Human Molecular GeneticsGTx, Inc. (GTXI) Reports Preclinical Study Results of SARMs in DMD Models Published in Human Molecular Genetics
www.streetinsider.com - May 3 at 3:03 PM
GTx Provides Corporate Update and Reports Fourth Quarter and Year-End 2016 Financial ResultsGTx Provides Corporate Update and Reports Fourth Quarter and Year-End 2016 Financial Results
us.rd.yahoo.com - March 16 at 3:56 AM
Q4 2016 GTX Inc Earnings Release - Before Market OpenQ4 2016 GTX Inc Earnings Release - Before Market Open
us.rd.yahoo.com - March 16 at 3:56 AM
GTx (GTXI) Dips on Quarterly LossGTx (GTXI) Dips on Quarterly Loss
www.baystreet.ca - March 15 at 5:54 PM
BRIEF-Gtx Inc qtrly loss per share $0.44BRIEF-Gtx Inc qtrly loss per share $0.44
www.reuters.com - March 15 at 5:54 PM
GTx beats by $0.13GTx beats by $0.13
seekingalpha.com - March 15 at 7:32 AM
GTX INC /DE/ Files SEC form 8-K, Change in Directors or Principal OfficersGTX INC /DE/ Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - January 14 at 4:46 AM
GTX INC /DE/ Files SEC form 8-K, Other EventsGTX INC /DE/ Files SEC form 8-K, Other Events
us.rd.yahoo.com - December 21 at 11:30 PM
Jefferies Cuts Price Target on GTx, Inc. (GTXI) to $7 Following Enobosarm Trial ResultsJefferies Cuts Price Target on GTx, Inc. (GTXI) to $7 Following Enobosarm Trial Results
www.streetinsider.com - December 9 at 10:14 AM

SEC Filings

GTX (NASDAQ:GTXI) SEC Filings

DateFilerForm TypeView

Social Media

Financials

GTX (NASDAQ:GTXI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

GTX (NASDAQ GTXI) Stock Chart for Monday, December, 11, 2017

Loading chart…

This page was last updated on 12/11/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.